Corwin A Robertson
Overview
Explore the profile of Corwin A Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robertson C, Jacqmein J, Selmani A, Galarza K, Oster P
Hum Vaccin Immunother
. 2024 Nov;
20(1):2426868.
PMID: 39555800
Stage I of this study (NCT04142242) demonstrated the safety and immunogenicity of a booster dose of a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) and immune persistence 3 and 6-7 ...
2.
Robertson C, Jacqmein J, Selmani A, Galarza K, Oster P
Hum Vaccin Immunother
. 2023 Jan;
19(1):2160600.
PMID: 36632042
This 2-stage Phase III study (NCT04142242) of a recently licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) assessed the safety and immunogenicity of a booster dose in older adults (≥59 years)...
3.
Marshall G, Pelton S, Robertson C, Oster P
Hum Vaccin Immunother
. 2022 Aug;
18(6):2099142.
PMID: 35947774
Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines...
4.
Robertson C, Hedrick J, Bassily E, Greenberg D
Vaccine
. 2019 Jan;
37(8):1016-1020.
PMID: 30670301
One dose of quadrivalent meningococcal conjugate vaccine (MenACWY) was first recommended for US adolescents (ages 11-12 years) in 2005 to protect against invasive meningococcal disease (IMD). In 2010, after evidence...
5.
Robertson C, Mercer M, Selmani A, Klein N, Jeanfreau R, Greenberg D
Pediatr Infect Dis J
. 2018 Nov;
38(3):323-328.
PMID: 30395011
Background: For children <3 years of age, a half dose of inactivated influenza vaccine (7.5 μg hemagglutinin per strain) has been used for more than 30 years, but several studies...
6.
Talbot H, Dunning A, Robertson C, Landolfi V, Greenberg D, DiazGranados C
Open Forum Infect Dis
. 2018 Jun;
5(6):ofy115.
PMID: 29942820
Passive surveillance data had signaled the possibility of gastrointestinal adverse events occurring after the administration of high-dose inactivated influenza vaccine (IIV-HD). However, in a large, prospective randomized clinical trial, rates...
7.
Greenberg D, Robertson C, Talbot H, Decker M
Hum Vaccin Immunother
. 2017 Jul;
13(9):2058-2064.
PMID: 28700265
Frequent mismatches between the predominant circulating B strain lineage and the B strain lineage in trivalent influenza vaccines have resulted in missed opportunities to prevent influenza illness. Quadrivalent influenza vaccines...
8.
Robertson C, DiazGranados C, Decker M, Chit A, Mercer M, Greenberg D
Expert Rev Vaccines
. 2016 Nov;
15(12):1495-1505.
PMID: 27813430
Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which...
9.
Robertson C, Greenberg D, Hedrick J, Pichichero M, Decker M, Saunders M
Vaccine
. 2016 Sep;
34(44):5273-5278.
PMID: 27642132
Background: Quadrivalent meningococcal conjugate vaccines (MenACWY) were developed to offer long-term protection against invasive disease caused by serogroups A, C, W, and Y. Reduced MenACWY effectiveness within 5 years after...
10.
DiazGranados C, Dunning A, Robertson C, Talbot H, Landolfi V, Greenberg D
Clin Infect Dis
. 2016 Aug;
63(9):1267.
PMID: 27506683
No abstract available.